Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Tipo de documento: | Trabalho de conclusão de curso |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFU |
Texto Completo: | https://repositorio.ufu.br/handle/123456789/33147 |
Resumo: | Cancer-related epidemiological data are alarming. In 2018, 18 million new cases were diagnosed worldwide, with 52% of these patients dying. In Brazil, the numbers are equally worrying, with 627,000 new diagnoses expected for the 2020-2022 triennium. The main systemic treatment is chemotherapy, capable of, in most cases, a progression of the disease, associated with effects associated with debilitating effects. In this scenario, immunotherapy has to define the promise and the revolutionary, by stimulating its own defense mechanisms in the containment of tumors. The Gc protein-derived macrophage activating factor (GcMAF) is thus evaluated and capable of inhibiting immunosuppression mediated by transformed cells. In the present study, we evaluated the modulatory effects of GcMAF in Drosophila melanogaster using the epithelial tumor test (ETT) to predict its anticarcinogenicity in an experimental model that has high genetic homology with mammals. GcMAF isolated in the configurations (25pg / ml, 50pg / ml and 100pg / ml), Vitamin D (VD-1mM), Doxorubicin (DOX-0.4mM) and as flats, GcMAF + VD, GcMAF + DOX, GcMAF + VD + DOX is also not a toxicity for D. melanogaster, these being the conditions evaluated in the ETT. Isolated GcMAF was not carcinogenic in any of the evaluated recommendations, nor when associated with VD. How to join GcMAF + DOX and GcMAF + DOX + VD dissipating modulatory effect on the carcinogenicity of DOX, with a reduction in the frequency of tumors when compared to the positive control (DOX - 0.4mM). Our study helps to understand the role of GcMAF in tumor control, allowing us to better characterize it as a cancer treatment strategy. |
id |
UFU_b89bf780321579bba65e84afcd055e5e |
---|---|
oai_identifier_str |
oai:repositorio.ufu.br:123456789/33147 |
network_acronym_str |
UFU |
network_name_str |
Repositório Institucional da UFU |
repository_id_str |
|
spelling |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAFDrosophila melanogaster as a model for evaluating the anti-carcinogenicity of GcMAFGcMAF. Drosophila melanogaster. Carcinogênese. Imunoterapia.GcMAF. Drosophila melanogaster. Carcinogenesis. Immunotherapy.CNPQ::CIENCIAS BIOLOGICASCNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIACNPQ::CIENCIAS BIOLOGICAS::GENETICACancer-related epidemiological data are alarming. In 2018, 18 million new cases were diagnosed worldwide, with 52% of these patients dying. In Brazil, the numbers are equally worrying, with 627,000 new diagnoses expected for the 2020-2022 triennium. The main systemic treatment is chemotherapy, capable of, in most cases, a progression of the disease, associated with effects associated with debilitating effects. In this scenario, immunotherapy has to define the promise and the revolutionary, by stimulating its own defense mechanisms in the containment of tumors. The Gc protein-derived macrophage activating factor (GcMAF) is thus evaluated and capable of inhibiting immunosuppression mediated by transformed cells. In the present study, we evaluated the modulatory effects of GcMAF in Drosophila melanogaster using the epithelial tumor test (ETT) to predict its anticarcinogenicity in an experimental model that has high genetic homology with mammals. GcMAF isolated in the configurations (25pg / ml, 50pg / ml and 100pg / ml), Vitamin D (VD-1mM), Doxorubicin (DOX-0.4mM) and as flats, GcMAF + VD, GcMAF + DOX, GcMAF + VD + DOX is also not a toxicity for D. melanogaster, these being the conditions evaluated in the ETT. Isolated GcMAF was not carcinogenic in any of the evaluated recommendations, nor when associated with VD. How to join GcMAF + DOX and GcMAF + DOX + VD dissipating modulatory effect on the carcinogenicity of DOX, with a reduction in the frequency of tumors when compared to the positive control (DOX - 0.4mM). Our study helps to understand the role of GcMAF in tumor control, allowing us to better characterize it as a cancer treatment strategy.Pesquisa sem auxílio de agências de fomentoTrabalho de Conclusão de Curso (Graduação)Os dados epidemiológicos relacionados ao câncer são alarmantes. Em 2018, foram diagnosticados, mundialmente, 18 milhões de novos casos, sendo que 52% destes pacientes vieram a óbito. No Brasil, os números são igualmente preocupantes, sendo esperados 627 mil novos diagnósticos para o triênio de 2020-2022. O principal tratamento sistêmico é a quimioterapia, capaz de conter, na maioria dos casos, a progressão da doença, contudo associada a efeitos colaterais debilitantes. Nesse cenário, a imunoterapia tem se mostrado promissora e revolucionária, ao estimular os próprios mecanismos de defesa na contenção de tumores. O fator de ativação de macrófagos derivado da proteína Gc (GcMAF) é assim classificado e capaz de inibir a imunossupressão mediada pelas células transformadas. No presente estudo avaliamos os efeitos moduladores do GcMAF em Drosophila melanogaster utilizando o teste de tumores epiteliais (ETT) para predizer sua anticarcinogenicidade em um modelo experimental que apresenta elevada homologia genética com mamíferos. GcMAF isolado nas concentrações (25pg/ml, 50pg/ml e 100pg/ml), Vitamina D (VD-1mM), Doxorrubicina (DOX-0,4mM) e as combinações, GcMAF + VD, GcMAF + DOX, GcMAF + VD + DOX também não apresentaram toxicidade a D. melanogaster, sendo estas as condições avaliadas no ETT. GcMAF isolado não foi carcinogênico em nenhuma das concentrações avaliadas e nem quando associado a VD. As combinações GcMAF + DOX e GcMAF + DOX + VD apresentaram significativo efeito modulador sobre a carcinogenicidade da DOX, com redução na frequência de tumores quando comparado ao controle positivo (DOX – 0,4mM). Nosso estudo auxiliará na compreensão do papel do GcMAF no controle de tumores, permitindo melhor caracterizá-lo enquanto estratégia de tratamento oncológico.2023-10-28Universidade Federal de UberlândiaBrasilBiotecnologiaLima, Paula Marynella Alves Pereirahttp://lattes.cnpq.br/5579976179167113Araújo, Thaise Gonçalves dehttp://lattes.cnpq.br/3348615812243880Orsolin, Priscila Capelarihttp://lattes.cnpq.br/7907169136625334Machado, Nayane Moreirahttp://lattes.cnpq.br/4916306597801021Campos, Lauander Silva2021-11-05T16:05:18Z2021-11-05T16:05:18Z2021-10-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisapplication/pdfCAMPOS, Lauander Silva. Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF. 2021. 44 f. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) - Universidade Federal de Uberlândia, Patos de Minas, 2021.https://repositorio.ufu.br/handle/123456789/33147porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFUinstname:Universidade Federal de Uberlândia (UFU)instacron:UFU2023-11-08T14:02:08Zoai:repositorio.ufu.br:123456789/33147Repositório InstitucionalONGhttp://repositorio.ufu.br/oai/requestdiinf@dirbi.ufu.bropendoar:2023-11-08T14:02:08Repositório Institucional da UFU - Universidade Federal de Uberlândia (UFU)false |
dc.title.none.fl_str_mv |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF Drosophila melanogaster as a model for evaluating the anti-carcinogenicity of GcMAF |
title |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF |
spellingShingle |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF Campos, Lauander Silva GcMAF. Drosophila melanogaster. Carcinogênese. Imunoterapia. GcMAF. Drosophila melanogaster. Carcinogenesis. Immunotherapy. CNPQ::CIENCIAS BIOLOGICAS CNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIA CNPQ::CIENCIAS BIOLOGICAS::GENETICA |
title_short |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF |
title_full |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF |
title_fullStr |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF |
title_full_unstemmed |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF |
title_sort |
Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF |
author |
Campos, Lauander Silva |
author_facet |
Campos, Lauander Silva |
author_role |
author |
dc.contributor.none.fl_str_mv |
Lima, Paula Marynella Alves Pereira http://lattes.cnpq.br/5579976179167113 Araújo, Thaise Gonçalves de http://lattes.cnpq.br/3348615812243880 Orsolin, Priscila Capelari http://lattes.cnpq.br/7907169136625334 Machado, Nayane Moreira http://lattes.cnpq.br/4916306597801021 |
dc.contributor.author.fl_str_mv |
Campos, Lauander Silva |
dc.subject.por.fl_str_mv |
GcMAF. Drosophila melanogaster. Carcinogênese. Imunoterapia. GcMAF. Drosophila melanogaster. Carcinogenesis. Immunotherapy. CNPQ::CIENCIAS BIOLOGICAS CNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIA CNPQ::CIENCIAS BIOLOGICAS::GENETICA |
topic |
GcMAF. Drosophila melanogaster. Carcinogênese. Imunoterapia. GcMAF. Drosophila melanogaster. Carcinogenesis. Immunotherapy. CNPQ::CIENCIAS BIOLOGICAS CNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIA CNPQ::CIENCIAS BIOLOGICAS::GENETICA |
description |
Cancer-related epidemiological data are alarming. In 2018, 18 million new cases were diagnosed worldwide, with 52% of these patients dying. In Brazil, the numbers are equally worrying, with 627,000 new diagnoses expected for the 2020-2022 triennium. The main systemic treatment is chemotherapy, capable of, in most cases, a progression of the disease, associated with effects associated with debilitating effects. In this scenario, immunotherapy has to define the promise and the revolutionary, by stimulating its own defense mechanisms in the containment of tumors. The Gc protein-derived macrophage activating factor (GcMAF) is thus evaluated and capable of inhibiting immunosuppression mediated by transformed cells. In the present study, we evaluated the modulatory effects of GcMAF in Drosophila melanogaster using the epithelial tumor test (ETT) to predict its anticarcinogenicity in an experimental model that has high genetic homology with mammals. GcMAF isolated in the configurations (25pg / ml, 50pg / ml and 100pg / ml), Vitamin D (VD-1mM), Doxorubicin (DOX-0.4mM) and as flats, GcMAF + VD, GcMAF + DOX, GcMAF + VD + DOX is also not a toxicity for D. melanogaster, these being the conditions evaluated in the ETT. Isolated GcMAF was not carcinogenic in any of the evaluated recommendations, nor when associated with VD. How to join GcMAF + DOX and GcMAF + DOX + VD dissipating modulatory effect on the carcinogenicity of DOX, with a reduction in the frequency of tumors when compared to the positive control (DOX - 0.4mM). Our study helps to understand the role of GcMAF in tumor control, allowing us to better characterize it as a cancer treatment strategy. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-05T16:05:18Z 2021-11-05T16:05:18Z 2021-10-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
format |
bachelorThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
CAMPOS, Lauander Silva. Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF. 2021. 44 f. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) - Universidade Federal de Uberlândia, Patos de Minas, 2021. https://repositorio.ufu.br/handle/123456789/33147 |
identifier_str_mv |
CAMPOS, Lauander Silva. Drosophila melanogaster como modelo para a avaliação da anticarcinogenicidade do GcMAF. 2021. 44 f. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) - Universidade Federal de Uberlândia, Patos de Minas, 2021. |
url |
https://repositorio.ufu.br/handle/123456789/33147 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Uberlândia Brasil Biotecnologia |
publisher.none.fl_str_mv |
Universidade Federal de Uberlândia Brasil Biotecnologia |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFU instname:Universidade Federal de Uberlândia (UFU) instacron:UFU |
instname_str |
Universidade Federal de Uberlândia (UFU) |
instacron_str |
UFU |
institution |
UFU |
reponame_str |
Repositório Institucional da UFU |
collection |
Repositório Institucional da UFU |
repository.name.fl_str_mv |
Repositório Institucional da UFU - Universidade Federal de Uberlândia (UFU) |
repository.mail.fl_str_mv |
diinf@dirbi.ufu.br |
_version_ |
1805569570041233408 |